Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Friedemann Schmidt

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Journal of Pharmacological and Toxicological Methods|July 22, 2018
In vitro secondary pharmacological profiling: An IQ-DruSafe industry survey on current practicesJean-Pierre Valentin, Jean-Michel Guillon, Stephen Jenkinson, et al.
Journal of Medicinal Chemistry|December 21, 2021
Rational Design of Highly Potent, Selective, and Bioavailable SGK1 Protein Kinase Inhibitors for the Treatment of OsteoarthritisNis Halland, Friedemann Schmidt, Tilo Weiss, et al.
ACS Medicinal Chemistry Letters|January 16, 2015
Discovery of N-[4-(1H-Pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides as Highly Active and Selective SGK1 InhibitorsNis Halland, Friedemann Schmidt, Tilo Weiss, et al.
Journal of Biochemical and Molecular Toxicology|May 9, 2019
Mechanistic investigations of the liver toxicity of the free fatty acid receptor 1 agonist fasiglifam (TAK875) and its primary metabolitesTimothy Ackerson, Alexander Amberg, Jens Atzrodt, et al.
Nature Reviews. Drug Discovery|June 17, 2024
Author Correction: The state of the art in secondary pharmacology and its impact on the safety of new medicinesRichard J Brennan, Stephen Jenkinson, Andrew Brown, et al.
Nature Reviews. Drug Discovery|May 21, 2024
The state of the art in secondary pharmacology and its impact on the safety of new medicinesRichard J Brennan, Stephen Jenkinson, Andrew Brown, et al.
Frontiers in Toxicology|April 22, 2024
Developing a pragmatic consensus procedure supporting the ICH S1B(R1) weight of evidence carcinogenicity assessmentArianna Bassan, Ronald Steigerwalt, Douglas Keller, et al.
Bioorganic & Medicinal Chemistry Letters|March 13, 2012
Thiadiazoles as new inhibitors of diacylglycerol acyltransferase type 1Patrick Mougenot, Claudie Namane, Eykmar Fett, et al.
Bioorganic & Medicinal Chemistry Letters|December 3, 2015
Synthesis and multiparametric evaluation of thiadiazoles and oxadiazoles as diacylglycerol acyltransferase type 1 inhibitorsPatrick Mougenot, Claudie Namane, Eykmar Fett, et al.
Nature Reviews. Drug Discovery|October 28, 2025
Quantitative systems toxicology: modelling to mechanistically understand and predict drug safetyChristopher E Goldring, Giusy Russomanno, Carmen Pin, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Journal of Pharmacological and Toxicological Methods|July 22, 2018
In vitro secondary pharmacological profiling: An IQ-DruSafe industry survey on current practicesJean-Pierre Valentin, Jean-Michel Guillon, Stephen Jenkinson, et al.
Journal of Medicinal Chemistry|December 21, 2021
Rational Design of Highly Potent, Selective, and Bioavailable SGK1 Protein Kinase Inhibitors for the Treatment of OsteoarthritisNis Halland, Friedemann Schmidt, Tilo Weiss, et al.
ACS Medicinal Chemistry Letters|January 16, 2015
Discovery of N-[4-(1H-Pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides as Highly Active and Selective SGK1 InhibitorsNis Halland, Friedemann Schmidt, Tilo Weiss, et al.
Journal of Biochemical and Molecular Toxicology|May 9, 2019
Mechanistic investigations of the liver toxicity of the free fatty acid receptor 1 agonist fasiglifam (TAK875) and its primary metabolitesTimothy Ackerson, Alexander Amberg, Jens Atzrodt, et al.
Nature Reviews. Drug Discovery|June 17, 2024
Author Correction: The state of the art in secondary pharmacology and its impact on the safety of new medicinesRichard J Brennan, Stephen Jenkinson, Andrew Brown, et al.
Nature Reviews. Drug Discovery|May 21, 2024
The state of the art in secondary pharmacology and its impact on the safety of new medicinesRichard J Brennan, Stephen Jenkinson, Andrew Brown, et al.
Frontiers in Toxicology|April 22, 2024
Developing a pragmatic consensus procedure supporting the ICH S1B(R1) weight of evidence carcinogenicity assessmentArianna Bassan, Ronald Steigerwalt, Douglas Keller, et al.
Bioorganic & Medicinal Chemistry Letters|March 13, 2012
Thiadiazoles as new inhibitors of diacylglycerol acyltransferase type 1Patrick Mougenot, Claudie Namane, Eykmar Fett, et al.
Bioorganic & Medicinal Chemistry Letters|December 3, 2015
Synthesis and multiparametric evaluation of thiadiazoles and oxadiazoles as diacylglycerol acyltransferase type 1 inhibitorsPatrick Mougenot, Claudie Namane, Eykmar Fett, et al.
Nature Reviews. Drug Discovery|October 28, 2025
Quantitative systems toxicology: modelling to mechanistically understand and predict drug safetyChristopher E Goldring, Giusy Russomanno, Carmen Pin, et al.
Pageof 3